The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G

Abstract:

INTRODUCTION:The main prognostic variables in early breast cancer are tumor size, histological grade, estrogen receptor/progesterone receptor (ER/PgR) status, number of positive nodes and human epidermal growth factor receptor 2 (HER2) status. The present study evaluated the prognostic and/or predictive value of vascular endothelial growth factor (VEGF) family members in high-risk early breast cancer patients treated with adjuvant chemo-hormonotherapy. METHODS:RNA was isolated from 308 formalin-fixed paraffin-embedded primary tumor samples from breast cancer patients enrolled in the HE10/97 trial, evaluating adjuvant dose-dense sequential chemotherapy with epirubicin followed by cyclophosphamide, methotrexate, fluorouracil (CMF) with or without paclitaxel (E-T-CMF versus E-CMF). A fully automated method based on magnetic beads was applied for RNA extraction, followed by one-step quantitative RT-PCR for mRNA analysis of VEGF-A, -B, -C and vascular endothelial growth factor receptor (VEGFR) 1, 2, 3. RESULTS:With a median follow-up of 8 years, 109 patients (35%) developed a relapse and 80 patients (26%) died. In high VEGF-C and VEGFR1 mRNA expressing tumors, ER/PgR-negative tumors (Fisher's exact test, P = 0.001 and P = 0.021, respectively) and HER2-positive tumors (P <0.001 and P = 0.028, respectively) were more frequent than in low VEGF-C and VEGFR1 expressing tumors, respectively. From the VEGF family members evaluated, high VEGFR1 mRNA expression (above the 75th percentile) emerged as a significant negative prognostic factor for overall survival (OS; hazard ratio (HR) = 1.60, 95% confidence interval (CI): 1.01 to 2.55, Wald's P = 0.047) and disease-free survival (DFS; HR = 1.67, 95% CI: 1.13 to 2.48, P = 0.010), when adjusting for treatment group. High VEGF-C mRNA expression was predictive for benefit from adjuvant treatment with paclitaxel (E-T-CMF arm) for OS (test for interaction, Wald's P = 0.038), while in multivariate analysis the interaction of VEGF-C with taxane treatment was significant for both OS (Wald's P = 0.019) and DFS (P = 0.041) and continuous VEGF-B mRNA expression values for OS (P = 0.019). CONCLUSIONS:The present study reports, for the first time, that VEGF-C mRNA overexpression, as assessed by qRT-PCR, has a strong predictive value in high-risk early breast cancer patients undergoing adjuvant paclitaxel-containing treatment. Further studies are warranted to validate the prognostic and/or predictive value of VEGF-B, VEGF-C and VEGFR1 in patients treated with adjuvant therapies and to reveal which members of the VEGF family could possibly be useful markers in identifying patients who will benefit most from anti-VEGF strategies. TRIAL REGISTRATION:Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12611000506998.

journal_name

Breast Cancer Res

authors

Linardou H,Kalogeras KT,Kronenwett R,Kouvatseas G,Wirtz RM,Zagouri F,Gogas H,Christodoulou C,Koutras AK,Samantas E,Pectasides D,Bafaloukos D,Fountzilas G

doi

10.1186/bcr3354

subject

Has Abstract

pub_date

2012-11-12 00:00:00

pages

R145

issue

6

eissn

1465-5411

issn

1465-542X

pii

bcr3354

journal_volume

14

pub_type

杂志文章,随机对照试验
  • Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165].

    abstract:INTRODUCTION:Isoflavones are hypothesized to protect against breast cancer, but it is not clear whether they act as oestrogens or anti-oestrogens in breast tissue. Our aim was to determine the effects of taking a red clover-derived isoflavone supplement daily for 1 year on mammographic breast density. Effects on oestra...

    journal_title:Breast cancer research : BCR

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1186/bcr773

    authors: Atkinson C,Warren RM,Sala E,Dowsett M,Dunning AM,Healey CS,Runswick S,Day NE,Bingham SA

    更新日期:2004-01-01 00:00:00

  • Alternative splicing and the progesterone receptor in breast cancer.

    abstract::Progesterone receptor status is a marker for hormone responsiveness and disease prognosis in breast cancer. Progesterone receptor negative tumours have generally been shown to have a poorer prognosis than progesterone receptor positive tumours. The observed loss of progesterone receptor could be through a range of mec...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2097

    authors: Cork DM,Lennard TW,Tyson-Capper AJ

    更新日期:2008-01-01 00:00:00

  • Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A.

    abstract:INTRODUCTION:This study was designed to determine if and how a non-toxic, naturally occurring bioflavonoid, galangin, affects proliferation of human mammary tumor cells. Our previous studies demonstrated that, in other cell types, galangin is a potent inhibitor of the aryl hydrocarbon receptor (AhR), an environmental c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1391

    authors: Murray TJ,Yang X,Sherr DH

    更新日期:2006-01-01 00:00:00

  • Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.

    abstract:BACKGROUND:Women with breast cancer who have multiple affected relatives are more likely to have inherited genetic risk factors for the disease. All the currently known genetic risk factors for breast cancer account for less than half of the average familial risk. Furthermore, the genetic factor(s) underlying an increa...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0825-6

    authors: Walker LC,Pearson JF,Wiggins GA,Giles GG,Hopper JL,Southey MC

    更新日期:2017-03-16 00:00:00

  • Breast cancer prognosis by combinatorial analysis of gene expression data.

    abstract:INTRODUCTION:The potential of applying data analysis tools to microarray data for diagnosis and prognosis is illustrated on the recent breast cancer dataset of van 't Veer and coworkers. We re-examine that dataset using the novel technique of logical analysis of data (LAD), with the double objective of discovering patt...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1512

    authors: Alexe G,Alexe S,Axelrod DE,Bonates TO,Lozina II,Reiss M,Hammer PL

    更新日期:2006-01-01 00:00:00

  • Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.

    abstract:INTRODUCTION:Laboratory and epidemiologic studies have suggested a modifying effect of cardiac glycosides (for example, digoxin and digitoxin) on cancer risk. We explored the association between digoxin treatment and invasive breast cancer incidence among postmenopausal Danish women. METHODS:We used Danish registries ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2205

    authors: Ahern TP,Lash TL,Sørensen HT,Pedersen L

    更新日期:2008-01-01 00:00:00

  • Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    abstract:INTRODUCTION:Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer subtypes. We previous...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2156

    authors: Habibi G,Leung S,Law JH,Gelmon K,Masoudi H,Turbin D,Pollak M,Nielsen TO,Huntsman D,Dunn SE

    更新日期:2008-01-01 00:00:00

  • Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.

    abstract::HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 amplification but wit...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3406

    authors: Acharyya S

    更新日期:2013-04-23 00:00:00

  • The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

    abstract:INTRODUCTION:Estrogens play a pivotal role in the initiation and progression of breast cancer. The genes that mediate these processes are not fully defined, but potentially include the known mammary oncogene MYC. Characterization of estrogen-target genes may help to elucidate further the mechanisms of estrogen-induced ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1985

    authors: Butt AJ,Sergio CM,Inman CK,Anderson LR,McNeil CM,Russell AJ,Nousch M,Preiss T,Biankin AV,Sutherland RL,Musgrove EA

    更新日期:2008-01-01 00:00:00

  • Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

    abstract:INTRODUCTION:Human epidermal growth factor receptor-2 (HER2) gene amplification (HER2+) drives tumor cell growth and survival in ~25% of breast cancers. HER2 signaling activates the type I phosphoinositide 3-kinase (PI3K), upon which these tumors rely. Consequently, inhibitors of HER2 and type I PI3K block growth and i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0656-2

    authors: Young CD,Arteaga CL,Cook RS

    更新日期:2015-12-04 00:00:00

  • Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

    abstract::Many women newly diagnosed with breast cancer and with a strong family history of breast cancer are referred to a family cancer service for genetic counselling and for consideration of genetic testing for germline mutations in cancer predisposition genes following completion of their cancer treatment. However, there i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2194

    authors: Meiser B,Tucker K,Friedlander M,Barlow-Stewart K,Lobb E,Saunders C,Mitchell G

    更新日期:2008-01-01 00:00:00

  • Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

    abstract:INTRODUCTION:The amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer pat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2150

    authors: Lundgren K,Holm K,Nordenskjöld B,Borg A,Landberg G

    更新日期:2008-01-01 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract:BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-020-01349-9

    authors: O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期:2020-10-27 00:00:00

  • Comparison of percent density from raw and processed full-field digital mammography data.

    abstract:INTRODUCTION:Mammographic density has been established as a strong risk factor for breast cancer, primarily using digitized film mammograms. Full-field digital mammography (FFDM) is replacing film mammography, has different properties than film, and provides both raw and processed clinical display representation images...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3372

    authors: Vachon CM,Fowler EE,Tiffenberg G,Scott CG,Pankratz VS,Sellers TA,Heine JJ

    更新日期:2013-01-04 00:00:00

  • Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank.

    abstract:INTRODUCTION:Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Ca...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3627

    authors: Pardo I,Lillemoe HA,Blosser RJ,Choi M,Sauder CA,Doxey DK,Mathieson T,Hancock BA,Baptiste D,Atale R,Hickenbotham M,Zhu J,Glasscock J,Storniolo AM,Zheng F,Doerge RW,Liu Y,Badve S,Radovich M,Clare SE,Susan G. Komen f

    更新日期:2014-03-17 00:00:00

  • Breast cancer intra-tumor heterogeneity.

    abstract::In recent years it has become clear that cancer cells within a single tumor can display striking morphological, genetic and behavioral variability. Burgeoning genetic, epigenetic and phenomenological data support the existence of intra-tumor genetic heterogeneity in breast cancers; however, its basis is yet to be full...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3658

    authors: Martelotto LG,Ng CK,Piscuoglio S,Weigelt B,Reis-Filho JS

    更新日期:2014-05-20 00:00:00

  • Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

    abstract:INTRODUCTION:The re-emergence of the tumour growth factor-beta (TGF-beta)-related embryonic morphogen Nodal has recently been reported in several different human cancers. In this study, we examined the expression of Nodal in a series of benign and malignant human breast tissues to determine the clinical significance of...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3185

    authors: Strizzi L,Hardy KM,Margaryan NV,Hillman DW,Seftor EA,Chen B,Geiger XJ,Thompson EA,Lingle WL,Andorfer CA,Perez EA,Hendrix MJ

    更新日期:2012-05-11 00:00:00

  • Measuring proliferation in breast cancer: practicalities and applications.

    abstract::Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and immunohistochemistry of proliferation-associated antigens. The evidence, advantages and disadvantages for each of these methods along with ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1618

    authors: Beresford MJ,Wilson GD,Makris A

    更新日期:2006-01-01 00:00:00

  • Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

    abstract::Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because mutational inactivation of gene function is specific to tumor ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr26

    authors: Obermiller PS,Tait DL,Holt JT

    更新日期:2000-01-01 00:00:00

  • Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

    abstract:INTRODUCTION:Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0528-9

    authors: Ren XR,Wang J,Osada T,Mook RA Jr,Morse MA,Barak LS,Lyerly HK,Chen W

    更新日期:2015-02-15 00:00:00

  • Clinical trial update: National Cancer Institute of Canada.

    abstract::The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has al...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr979

    authors: Pritchard K,Whelan T

    更新日期:2005-01-01 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract:INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1843

    authors: Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期:2008-01-01 00:00:00

  • PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

    abstract:INTRODUCTION:Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly expressed in Human Epidermal Growth Factor 2(+) (Her2(+)) breast cancers. Overexpression of PTK6 enhances anchorage-independent survival, proliferation, and migration of breast cancer cells. We hypothesized that PTK6 inhibiti...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0594-z

    authors: Park SH,Ito K,Olcott W,Katsyv I,Halstead-Nussloch G,Irie HY

    更新日期:2015-06-19 00:00:00

  • Tracking the genomic evolution of breast cancer metastasis.

    abstract::Therapeutic choices for metastatic tumors are, in most cases, based upon the histological and molecular analysis of the corresponding primary tumor. Understanding whether and to what extent the genomic landscape of metastasis differs from the tumors from which they originated is critical yet largely unknown. A recent ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2469

    authors: Zecchin D,Bardelli A

    更新日期:2010-01-01 00:00:00

  • ‘The charmingest place’: non-coding RNA, lineage tracing, tumor heterogeneity, metastasis and metabolism--new methods in mammary gland development and cancer: the fifth ENBDC Workshop.

    abstract::The European Network for Breast Development and Cancer (ENBDC) Workshop on ‘Methods in Mammary Gland Development and Cancer’ has grown into the essential, international technical discussion forum for scientists with interests in the normal and neoplastic breast. The fifth ENBDC meeting was held in Weggis, Switzerland ...

    journal_title:Breast cancer research : BCR

    pub_type:

    doi:10.1186/bcr3497

    authors: Clarke RB,Stingl J,Vivanco M,Bentires-Alj M

    更新日期:2013-01-01 00:00:00

  • Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

    abstract:BACKGROUND:Several anthropometric measures have been found to be associated with the risk of breast cancer. Current weight, body mass index, and adult weight gain appear to be predictors of postmenopausal breast cancer. These factors have been associated with a reduced risk of premenopausal breast cancer. We asked whet...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1293

    authors: Kotsopoulos J,Olopado OI,Ghadirian P,Lubinski J,Lynch HT,Isaacs C,Weber B,Kim-Sing C,Ainsworth P,Foulkes WD,Eisen A,Sun P,Narod SA

    更新日期:2005-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract:BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1128-x

    authors: Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期:2019-03-28 00:00:00

  • NHERF1: molecular brake on the PI3K pathway in breast cancer.

    abstract::The adaptor protein NHERF1/EBP50 (Na/H exchanger regulatory factor 1/ezrin-radixin-moesin-binding phosphoprotein 50) emerged recently as an important player in breast cancer progression. Consisting of two tandem PDZ domains linked to a carboxyl-terminal ezrin-binding region, NHERF1 assembles macromolecular complexes a...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,社论

    doi:10.1186/bcr1992

    authors: Georgescu MM

    更新日期:2008-01-01 00:00:00

  • Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

    abstract:INTRODUCTION:Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may var...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0619-7

    authors: Morancho B,Martínez-Barriocanal Á,Villanueva J,Arribas J

    更新日期:2015-08-12 00:00:00

  • Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research.

    abstract::The potential for a reduction in dietary fat or for an increase in dietary fiber to reduce breast cancer risk has been debated for some years. It is argued here that available research data, even though extensive, leave open hypotheses ranging from little or no potential to major public health potential for breast can...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr68

    authors: Prentice RL

    更新日期:2000-01-01 00:00:00